Document:

Exhibit 10.2

 

SEPARATION AGREEMENT AND RELEASE

 

This Separation
Agreement and Release (“Agreement”) is made by and between Martín Sebastian Olivo, M.D. (“Employee”) and
Protara Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred
to as a “Party”).

 

RECITALS

 

WHEREAS, Employee was employed by the Company;

 

WHEREAS, Employee
signed an Executive Employment Agreement with the Company effective April 19, 2021 (the “Executive Employment Agreement”);

 

WHEREAS, Employee
signed an Employee Confidential Information and Inventions Assignment Agreement with the Company on or around April 9, 2021 (the “Confidentiality
Agreement”), attached as Exhibit A;

 

WHEREAS, the
Company granted Employee the option to purchase 120,000 shares of the Company’s common stock (the “Option”), subject
to the terms and conditions of the Company’s 2020 Inducement Plan (the “Inducement Plan”) and the Stock Option Agreement
between Employee and the Company (the “Stock Option Agreement”, and collectively with the Inducement Plan, the “Stock
Agreements”);

 

WHEREAS, Employee
separated from employment with the Company effective October 15, 2021 (the “Separation Date”); and

 

WHEREAS, the Parties
wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Employee may have
against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in
any way related to Employee’s employment with or separation from the Company;

 

NOW, THEREFORE,
in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows:

 

COVENANTS

 

1. 
Consideration. In consideration of Employee’s execution of this Agreement and Employee’s fulfillment of all
of its terms and conditions, and provided that Employee does not revoke the Agreement under the Acknowledgement of Waiver of Claims under
ADEA Section below, the Company agrees as follows:

 

a. 
Payment. Pursuant to Section 8(a)(i)(A) of the Executive Employment Agreement, the Company agrees to pay Employee a lump
sum approximately equivalent to nine (9) months of Employee’s base salary, for a total of Three Hundred Twenty-Four Thousand Dollars
($324,000), less applicable withholding, within ten (10) business days after the Effective Date of this Agreement.

 

b. 
Additional Payment. The Company additionally agrees to pay Employee a lump sum total of One Hundred Twenty-Nine Thousand
Six Hundred Dollars ($129,600), less applicable withholding, within ten (10) business days after the Effective Date of this Agreement.
The Parties agree that this payment reflects the payment of nine (9) months of Employee’s target annual bonus for 2021 pursuant
to Section 8(a)(1)(C) of the Executive Employment Agreement and the Company’s waiver of the amount of the Signing Bonus that Employee
was otherwise required to repay the Company pursuant to Section 3(b) of the Executive Employment Agreement (as defined therein).

 

c.  
Pro Rata Vesting of Option. Notwithstanding that Employee was not employed through the one-year anniversary of the Grant
Date (as defined in the Stock Option Agreement), pursuant to Section 8(a)(i)(F) of the Executive Employment Agreement, the Company agrees
to accelerate the vesting of the Option such that Employee will be considered to have vested in such Option through, and no later than,
the Separation Date.

 

d.  COBRA.
Pursuant to Section 8(a)(i)(E) of the Executive Employment Agreement, the Company shall reimburse Employee for the payments Employee
makes for COBRA coverage for a period of nine (9) months, provided Employee timely elects and pays for COBRA coverage. COBRA
reimbursements shall be made by the Company to Employee consistent with the Company’s normal expense reimbursement policy,
provided that Employee submits documentation to the Company substantiating Employee’s payments for COBRA coverage.

 

    Page 1 of 9

     

    

 

e.  
Life Insurance Benefits. Pursuant to Section 8(a)(i)(E) of the Executive Employment Agreement, the Company shall reimburse
Employee for the payments Employee makes for supplemental life insurance coverage for a period of nine (9) months, provided Employee timely
elects and pays for such coverage. Supplemental life insurance reimbursements shall be made by the Company to Employee consistent with
the Company’s normal expense reimbursement policy, provided that Employee submits documentation to the Company substantiating Employee’s
payments for such coverage.

 

f.   
General. Employee acknowledges that without this Agreement, Employee is otherwise not entitled to the consideration listed
in this Section 1.

 

2.    
Stock. The Parties agree that, in consideration of Section 1(c) above, for purposes of determining the number of shares
of the Company’s common stock that Employee is entitled to purchase from the Company under the Option grant, pursuant to the exercise
of outstanding options, Employee will be considered to have vested only up to the Separation Date. Employee acknowledges that as of the
Separation Date, Employee will have vested in 12,500 options and no more. The exercise of Employee’s vested options and shares shall
continue to be governed by the terms and conditions of the Stock Agreements.

 

3. 
Benefits. Employee’s health insurance benefits shall cease on last day of the month in which the Separation Date occurs,
subject to Employee’s right to continue Employee’s health insurance under COBRA or comparable state law, if applicable. Employee’s
participation in all benefits and incidents of employment, including, but not limited to, vesting in stock options, and the accrual of
bonuses, vacation, and paid time off, ceased as of the Separation Date.

 

4. 
Payment of Salary and Receipt of All Benefits. Employee acknowledges and represents that, other than the consideration set
forth in this Agreement, the Company and its agents have paid or provided all salary, wages, bonuses, accrued vacation/paid time off,
notice periods, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses,
commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee, including, but not limited
to, termination payments required under the Executive Employment Agreement.

 

5. 
Release of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations
owed to Employee by the Company, ArTara Subsidiary, Inc., and their current and former respective officers, directors, employees, agents,
investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, professional employer organization
or co-employer, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively,
the “Releasees”). Employee, on Employee’s own behalf and on behalf of Employee’s respective heirs, family members,
executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to
institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of
any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising
from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement, including,
without limitation:

 

a. 
any and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of
that relationship;

 

b. 
any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the
Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable
state corporate law, and securities fraud under any state or federal law;

 

c.  any
and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment;
retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and
implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional
misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices;
defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and
disability benefits;

 

    Page 2 of 9

     

    

 

d. 
any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of
the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990;
the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the
Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification
Act; the Family and Medical Leave Act; the Uniformed Services Employment and Reemployment Rights Act; the New York State Human Rights
Law; the New York Executive Law; the New York Civil Practice Law and Rules; the New York Judiciary Law; the New York Corrections Law;
the New York Labor Law; the New York Civil Rights Law; the New York Administrative Code; the New York City Administrative Code; the New
York City Human Rights Law; the New York Hours of Labor Law; the New York Wage Payment Law; the New York Minimum Wage Act; the New York
Whistleblower Law; and the New York Off-Duty Conduct Lawful Activities Discrimination Law;

 

e.
any and all claims for violation of the federal or any state constitution;

 

f.  
any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

 

g. 
any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any
of the proceeds received by Employee as a result of this Agreement; and

 

h.
any and all claims for attorneys’ fees and costs.

 

Employee agrees that the release
set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This
release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released
as a matter of law, including any Protected Activity (as defined below). This release does not extend to any right Employee may have to
unemployment compensation benefits or workers’ compensation benefits. Employee represents that Employee has made no assignment or
transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this
Section. This release does not extend to any indemnification rights Employee has under any applicable insurance policy, contract, state
law or by-law.

 

6. 
Acknowledgment of Waiver of Claims under ADEA. Employee acknowledges that Employee is waiving and releasing any rights Employee
may have under the Age Discrimination in Employment Act of 1967 (“ADEA”) against the Releasees, and that this waiver and release
is knowing and voluntary. Employee agrees that this waiver and release does not apply to any rights or claims that may arise under the
ADEA after the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release is in
addition to anything of value to which Employee was already entitled. Employee further acknowledges that Employee has been advised by
this writing that: (a) Employee should consult with an attorney prior to executing this Agreement; (b) Employee has twenty-one
(21) days within which to consider this Agreement; (c) Employee has seven (7) days following Employee’s execution of this Agreement
to revoke this Agreement; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing in
this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver
under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal
law. In the event Employee signs this Agreement and returns it to the Company in less than the 21-day period identified above, Employee
hereby acknowledges that Employee has freely and voluntarily chosen to waive the time period allotted for considering this Agreement.
Employee acknowledges and understands that revocation must be accomplished by a written notification to the undersigned Company representative
that is received prior to the Effective Date. The Parties agree that changes, whether material or immaterial, do not restart the running
of the 21-day period.

 

7. 
No Pending or Future Lawsuits. Employee represents that Employee has no lawsuits, claims, or actions pending in Employee’s
name, or on behalf of any other person or entity, against the Company or any of the other Releasees. Employee also represents that Employee
does not intend to bring any claims on Employee’s own behalf or on behalf of any other person or entity against the Company or any
of the other Releasees.

 

8.  No
Right to Employment. Employee understands and agrees that, as a condition of this Agreement, Employee shall not be entitled to
any employment with the Company, and Employee hereby waives any right, or alleged right, of employment or re-employment with the
Company.

 

    Page 3 of 9

     

    

 

9. 
Confidentiality. Employee agrees to maintain in complete confidence the existence of this Agreement, the contents and terms
of this Agreement, and the consideration for this Agreement (hereinafter collectively referred to as “Separation Information”).
Except as required by law, court order or regulation, Employee may disclose Separation Information only to Employee’s immediate
family members, the Court in any proceedings to enforce the terms of this Agreement, Employee’s counsel, and Employee’s accountant
and any professional tax advisor to the extent that they need to know the Separation Information in order to provide advice on tax treatment
or to prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. Employee agrees that
Employee will not publicize, directly or indirectly, any Separation Information. Employee acknowledges and agrees that Employee does not
possess any claim or allegation, either asserted or otherwise, involving harassment or discrimination, that may be subject to or covered
under N.Y. C.P.L.R. § 5003-b and N.Y. General Obligations Law § 5-336.

 

10. 
Trade Secrets and Confidential Information/Company Property. Employee reaffirms and agrees to observe and abide by the terms
of the Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of the Company’s trade secrets
and confidential and proprietary information, noncompetition, and nonsolicitation of Company employees. Employee agrees that the above
reaffirmation and agreement with the Confidentiality Agreement shall constitute a new and separately enforceable agreement to abide by
the terms of the Confidentiality Agreement, entered and effective as of the Effective Date. Employee acknowledges and agrees that Employee
did not disclose any prior inventions on Exhibit A to the Confidentiality Agreement. Employee specifically acknowledges and agrees that
any violation of the restrictive covenants in the Confidentiality Agreement shall constitute a material breach of this Agreement. Employee’s
signature below constitutes Employee’s certification under penalty of perjury that Employee has returned all documents and other
items provided to Employee by the Company, developed or obtained by Employee in connection with Employee’s employment with the Company,
or otherwise belonging to the Company, including, but not limited to, all passwords to any software or other programs or data that Employee
used in performing services for the Company. Notwithstanding the foregoing, however, the Company agrees to allow Employee to keep Employee’s
Company-provided laptop until on or around November 22, 2021, or earlier if requested by the Company. Employee understands that his access
to Company files, e-mails, and other documents will be restricted as of the Separation Date.

 

11. 
No Third Party Cooperation. Employee agrees that Employee will not knowingly encourage, counsel, or assist any attorneys
or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third
party against any of the Releasees, unless under a subpoena or other court order to do so or as related directly to the ADEA waiver in
this Agreement. Employee agrees both to immediately notify the Company upon receipt of any such subpoena or court order, and to furnish,
within three (3) business days of its receipt, a copy of such subpoena or other court order. If approached by anyone for counsel or assistance
in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees,
Employee shall state no more than that Employee cannot provide counsel or assistance.

 

12. 
Cooperation with the Company. Employee agrees that Employee will assist and cooperate with the Company in connection with
the defense or prosecution of any claim that may be made against or by the Company or any Releasees, or in connection with any ongoing
or future investigation or dispute or claim of any kind involving the Company, including meeting with the Company’s counsel, any
proceeding before any arbitral, administrative, judicial, legislative, or other body or agency, including testifying in any proceeding
to the extent such claims, investigations or proceedings relate to services performed or required to be performed by Employee, pertinent
knowledge possessed by Employee, or any act or omission by Employee. Employee further agrees to perform all acts and execute and deliver
any documents that may be reasonably necessary to carry out the provisions of this paragraph.

 

13.  Communications.
Employee agrees to refrain from any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain from
any tortious interference with the contracts and relationships of any of the Releasees, including, but not limited to, anonymous or
named reviews, tweets, posts, or other comments published on the Internet.  Employee affirms that Employee has not disparaged
the Company from the Separation Date through the date Employee signs this Agreement. Employee furthers agrees that, by no later than
the Effective Date, Employee shall delete or otherwise remove any and all disparaging public comments or statements that Employee
made prior to the Effective Date about or relating to the Company, including, but not limited to, comments in online forums or on
websites (including, but not limited to, Facebook, Glassdoor, Yelp, and LinkedIn).  Employee shall direct any inquiries by
potential future employers to the Company’s human resources department, which shall use its best efforts to provide only the
Employee’s last position and dates of employment. Employee agrees to revise and update publicly available information,
including professional and social networking websites such as LinkedIn and Facebook, within four (4) weeks of the Separation Date to
remove any indication that Employee is employed by the Company. Employee’s violation of this provision shall be a material
breach of this Agreement.

 

    Page 4 of 9

     

    

 

14. 
Breach. In addition to the rights provided in the “Attorneys’ Fees” section below, Employee acknowledges
and agrees that any material breach of this Agreement, unless such breach constitutes a legal action by Employee challenging or seeking
a determination in good faith of the validity of the waiver herein under the ADEA, or of any provision of the Confidentiality Agreement
shall entitle the Company immediately to cease providing the consideration provided to Employee under this Agreement, recover the net
amounts paid to Employee under this Agreement, and to obtain damages, except as provided by law, provided, however, that
the Company shall not recover One Hundred Dollars ($100.00) of the consideration already paid pursuant to this Agreement and such amount
shall serve as full and complete consideration for the promises and obligations assumed by Employee under this Agreement and the Confidentiality
Agreement.

 

15. 
No Admission of Liability. Employee understands and acknowledges that this Agreement constitutes a compromise and settlement
of any and all actual or potential disputed claims by Employee. No action taken by the Company hereto, either previously or in connection
with this Agreement, shall be deemed or construed to be (a) an admission of the truth or falsity of any actual or potential claims or
(b) an acknowledgment or admission by the Company of any fault or liability whatsoever to Employee or to any third party.

 

16. 
Costs. The Parties shall each bear their own costs, attorneys’ fees, and other fees incurred in connection with the
preparation of this Agreement.

 

17. 
ARBITRATION. THE PARTIES AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS AGREEMENT, THEIR INTERPRETATION,
AND ANY OF THE MATTERS HEREIN RELEASED, SHALL BE SUBJECT TO ARBITRATION IN NEW YORK COUNTY, BEFORE THE JUDICIAL ARBITRATION AND MEDIATION
SERVICE (“JAMS”) UNDER ITS COMPREHENSIVE ARBITRATION RULES (“JAMS RULES”) AND NEW YORK LAW. THE COMPANY SHALL
BE RESPONSIBLE FOR PAYMENT OF ALL JAMS FEES, INCLUDING, BUT NOT LIMITED TO, THE FEES OF THE ARBITRATOR. THE ARBITRATOR MAY GRANT INJUNCTIONS
AND OTHER RELIEF IN SUCH DISPUTES. THE ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN ACCORDANCE WITH NEW YORK LAW, AND THE
ARBITRATOR SHALL APPLY SUBSTANTIVE AND PROCEDURAL NEW YORK LAW TO ANY DISPUTE OR CLAIM, WITHOUT REFERENCE TO ANY CONFLICT-OF-LAW PROVISIONS
OF ANY JURISDICTION. TO THE EXTENT THAT THE JAMS RULES CONFLICT WITH NEW YORK LAW, NEW YORK LAW SHALL TAKE PRECEDENCE. THE DECISION OF
THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT THE PREVAILING PARTY
IN ANY ARBITRATION SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE THE ARBITRATION AWARD. EACH
PARTY SHALL SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES; PROVIDED, HOWEVER, THAT THE ARBITRATOR SHALL AWARD ATTORNEYS’
FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW. THE PARTIES AGREE THAT PUNITIVE DAMAGES SHALL BE UNAVAILABLE IN ARBITRATION.
THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY. NOTWITHSTANDING
THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY OTHER PROVISIONAL REMEDY) FROM ANY COURT
HAVING JURISDICTION OVER THE PARTIES AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING TO THIS AGREEMENT AND THE AGREEMENTS INCORPORATED
HEREIN BY REFERENCE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED IN THIS PARAGRAPH CONFLICT WITH ANY OTHER ARBITRATION AGREEMENT
BETWEEN THE PARTIES, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT SHALL GOVERN.

 

18.  Authority.
The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company
and all who may claim through it to the terms and conditions of this Agreement. Employee represents and warrants that Employee has
the capacity to act on Employee’s own behalf and on behalf of all who might claim through Employee to bind them to the terms
and conditions of this Agreement. Each Party warrants and represents that there are no liens or claims of lien or assignments in law
or equity or otherwise of or against any of the claims or causes of action released herein.

 

    Page 5 of 9

     

    

 

19. 
Protected Activity. Employee understands that nothing in this Agreement shall in any way limit or prohibit Employee from
engaging for a lawful purpose in any Protected Activity, provided, however, that Employee agrees not to seek or accept any monetary award
from such a proceeding (except with respect to proceedings before the Securities and Exchange Commission). For purposes of this Agreement,
“Protected Activity” shall mean filing a charge, complaint, or report with, or otherwise communicating with, cooperating with
or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission,
including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration,
and the National Labor Relations Board (“Government Agencies”), or discussing the terms and conditions of Employee’s
employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act. Employee understands that in
connection with such Protected Activity, Employee is permitted to disclose documents or other information to Government Agencies as permitted
by law, and without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Employee agrees to
take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential
information under the Confidentiality Agreement to any parties other than the relevant Government Agencies. Employee further understands
that “Protected Activity” does not include the disclosure of any Company attorney-client privileged communications, and that
any such disclosure without the Company’s written consent shall constitute a material breach of this Agreement. In addition, pursuant
to the Defend Trade Secrets Act of 2016, Employee is notified that an individual will not be held criminally or civilly liable under any
federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government
official (directly or indirectly) or to an attorney solely for the purpose of reporting or investigating a suspected violation of law,
or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made under seal.
In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose
the trade secret to the individual’s attorney and use the trade secret information in the court proceeding, if the individual files
any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.

 

20. 
Waiver of Statutory Information Rights. Employee hereby waives any current or future rights Employee may have under Section
220 of the Delaware General Corporation Law (and similar rights under other applicable law) to inspect, or make copies and extracts from,
the Company’s stock ledger, any list of its stockholders, or any other books and records of the Company or any of its affiliates
or subsidiaries, in Employee’s capacity as a holder of stock, shares, units, options, or any other equity instrument.

 

21. 
No Representations. Employee represents that Employee has had an opportunity to consult with an attorney, and has carefully
read and understands the scope and effect of the provisions of this Agreement. Employee has not relied upon any representations or statements
made by the Company that are not specifically set forth in this Agreement. Employee acknowledges that there has been an opportunity to
negotiate the terms of this Agreement and that the Agreement will not be interpreted as an employer promulgated agreement.

 

22. 
Waiver. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof
unless such waiver shall have been duly executed in writing and delivered to the Party to be charged with such waiver. The failure of
any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver
of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement
shall be held to be a waiver of any other subsequent breach.

 

23. 
Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part
hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement
shall continue in full force and effect without said provision or portion of provision.

 

24. 
Attorneys’ Fees. Except with regard to a legal action challenging or seeking a determination in good faith of the
validity of the waiver herein under the ADEA, in the event that either Party brings an action to enforce or effect its rights under this
Agreement, the prevailing Party shall be entitled to recover its costs and expenses, including the costs of arbitration, litigation, court
fees, and reasonable attorneys’ fees incurred in connection with such an action.

 

25.  Entire
Agreement. This Agreement represents the entire agreement and understanding between the Company and Employee concerning the
subject matter of this Agreement and Employee’s employment with and separation from the Company and the events leading thereto
and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter
of this Agreement and Employee’s relationship with the Company, including the Executive Employment Agreement, with the
exception of the arbitration provision in the Executive Employment Agreement, the Confidentiality Agreement, and the Stock
Agreements.

 

    Page 6 of 9

     

    

 

26. 
No Oral Modification. This Agreement may only be amended in a writing signed by Employee and the Company’s Chief Executive
Officer.

 

27. 
Governing Law. This Agreement shall be governed by the laws of the State of New York, without regard for choice-of-law provisions.
Employee consents to personal and exclusive jurisdiction and venue in the State of New York.

 

28. 
Effective Date. Employee understands that this Agreement shall be null and void if not executed by Employee, and returned
to the Company, within the twenty-one (21) day period set forth above. Each Party has seven (7) days after that Party signs this Agreement
to revoke it. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been
signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”).

 

29. 
Counterparts. This Agreement may be executed in counterparts that may be executed, exchanged, and delivered by facsimile,
photo, e-mail PDF, Docusign/Echosign or a similarly accredited secure signature service, or other electronic transmission or signature.
Each counterpart will be deemed an original and all of which counterparts taken together shall have the same force and effect as an original
and shall constitute an effective, binding agreement on the part of each of the undersigned.

 

30. 
409A. The Parties intend that this Agreement will be administered in accordance with Section 409A of the Internal Revenue
Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Internal Revenue
Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Internal Revenue Code. 
The Parties agree that this Agreement may be amended, as reasonably requested by either Party, and as may be necessary to fully comply
with Section 409A of the Internal Revenue Code and all related rules and regulations in order to preserve the payments and benefits provided
hereunder without additional cost to either Party.

 

31. 
Voluntary Execution of Agreement. Employee understands and agrees that Employee executed this Agreement voluntarily, without
any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Employee’s
claims against the Company and any of the other Releasees. Employee acknowledges that:

 

		(a)	Employee has read this Agreement;

 

		(b)	Employee has been represented in the preparation, negotiation, and execution of
this Agreement by legal counsel of Employee’s own choice or has elected not to retain legal counsel;

 

		(c)	Employee understands the terms and consequences of this Agreement and of the releases
it contains; and

 

		(d)	Employee is fully aware of the legal and binding effect of this Agreement.

 

32. 
Consulting Agreement. Employee and the Company may execute a consulting agreement pursuant to which Employee may render
services to the Company for a period beginning on or after the Separation Date and ending on or about November 22, 2021.

 

[Signature Pages Follow]

 

    Page 7 of 9

     

    

 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the
respective dates set forth below.

 

	 	 	MARTÍN SEBASTIAN OLIVO, an individual
	 	 	 	 
	Dated:	Oct 15, 2021	 	/s/ Martín Sebastian Olivo
	 	 	Martín Sebastian Olivo
	 	 	 	 
	 	 	PROTARA THERAPEUTICS, INC.
	 	 	 	 
	Dated:	15-Oct-2021	 	By	/s/ Jesse Shefferman
	 	 	 	Jesse Shefferman
	 	 	 	Chief Executive Officer

 

    Page 8 of 9

     

    

 

EXHIBIT A

 

[Confidentiality Agreement]

 

 

Page 9 of 9Document

Exhibit 4.2

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 18, 2019, by and among Weave Communications, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
RECITALS
WHEREAS, the Company and certain of the Investors executed and delivered an Investors’ Rights Agreement, made as of November 19, 2018 (the “Existing Agreement”);
WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the Investors are entering into a Series D Preferred Stock Purchase Agreement (the “Purchase Agreement”) providing for the sale of shares of the Company’s Series D Preferred Stock;
WHEREAS, in connection with the Purchase Agreement, the parties desire to amend and restate the Existing Agreement as set forth in this Agreement; and
WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement;
NOW, THEREFORE, the parties hereby agree as follows:
1.    Definitions. For purposes of this Agreement:
1.1    “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director of such Person or any venture capital fund or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person.
1.2    “Board of Directors” means the Board of Directors of the Company.
1.3    “Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as the same may be amended from time to time.
1.4    “Common Stock” means shares of the Company’s common stock, par value $0.00001 per share.
1.5    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect 

thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.
1.6    “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.
1.7    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
1.8    “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.
1.9    “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.
1.10    “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.
1.11    “GAAP” means generally accepted accounting principles in the United States.
1.12    “Holder” means any holder of Registrable Securities who is a party to this Agreement.
1.13    “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships of a natural person referred to herein.
1.14    “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.
2

1.15    “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.
1.16    “Key Employee” means Brandon Rodman, Alan Taylor, Marty Smuin and Clint Berry, and any executive level employee (including any chief executive officer, chief financial officer, chief operating officer, chief information officer, president, division director or vice president-level position or any other comparable position) of the Company or any of its subsidiaries.
1.17    “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least 438,361 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof); provided, however, that solely with respect to Section 3, “Major Investor” shall include any Investor that, individually or together with such Investor’s Affiliates, holds at least 438,361 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof).
1.18    “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities (including, without limitation, any Derivate Securities).
1.19    “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.
1.20    “Preferred Stock” means, collectively, the Series D Preferred Stock, the Series C Preferred Stock, the Series B-1 Preferred Stock, the Series B Preferred Stock, the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series A-2 Preferred Stock, and the Series AA Preferred Stock (and any shares of Common Stock issued upon the conversion of any such series of the foregoing preferred stock).
1.21    “Qualified IPO” means the closing of the sale of shares of Common Stock in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act resulting in at least $75,000,000 of gross proceeds.
1.22    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Series D Preferred Stock, the Series C Preferred Stock, the Series B-1 Preferred Stock, the Series B Preferred Stock, the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series A-2 Preferred Stock or the Series AA Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to 
3

Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13.
1.23    “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.
1.24    “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b).
1.25    “SEC” means the Securities and Exchange Commission.
1.26    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.
1.27    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.
1.28    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
1.29    “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.
1.30    “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.00001 per share.
1.31    “Series A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock, par value $0.00001 per share.
1.32    “Series A-2 Preferred Stock” means shares of the Company’s Series A-2 Preferred Stock, par value $0.00001 per share.
1.33    “Series AA Preferred Stock” means shares of the Company’s Series AA Preferred Stock, par value $0.00001 per share.
1.34    “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.00001 per share.
1.35    “Series B-1 Preferred Stock” means shares of the Company’s Series B-1 Preferred Stock, par value $0.00001 per share.
1.36    “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.00001 per share.
1.37    “Series D Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.00001 per share.
4

2.    Registration Rights. The Company covenants and agrees as follows:
2.1    Demand Registration.
(a)    Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least a majority of the Registrable Securities (in the case of (i) above) or thirty percent (30%) of the Registrable Securities (in the case of (ii) above) then outstanding that the Company file a Form S-1 registration statement pursuant to which the Initiating Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration statement, propose to sell Registrable Securities and such other securities (if any) (x) if pursuant to (i) above, which would qualify as a Qualified IPO or (y) if pursuant to (ii) above, the aggregate gross proceeds of which are at least $15,000,000, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.
(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.
(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or 
5

Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period other than an Excluded Registration.
(d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d).
2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6.
6

2.3    Underwriting Requirements.
(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to the Initiating Holders holding a majority of the Registrable Securities then held by all Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.
(b)    In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any 
7

Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below twenty five percent (25%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.
(c)    For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than eighty percent (80%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.
2.4    Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:
(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to thirty days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;
(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;
(c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other 
8

documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;
(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;
(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;
(f)    use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;
(g)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;
(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;
(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and
(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.
In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.
2.5    Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable 
9

Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.
2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $100,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.
2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.
2.8    Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:
(a)    To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any 
10

Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.
(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.
(c)    Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8.
11

(d)    To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.
(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.
(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.
2.9    Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any 
12

time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:
(a)    make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;
(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and
(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).
2.10    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9.
2.11    “Market Stand-off” Agreement. Each Investor hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO (subject to extension to comply with Section 2711 of the FINRA rules), or ninety (90) days in the case of any registration other than the IPO, (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or 
13

exercisable or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Investor or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Investor or an Immediate Family Member of the Investor, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Investors only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Investor further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Investors subject to such agreements, based on the number of shares subject to such agreements.
2.12    Restrictions on Transfer.
(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferor of any Preferred Stock or Registrable Securities will cause any proposed purchaser, pledgee, or transferee of such securities to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.
(b)    Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form:
THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.
14

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.
The Investors consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12.
(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the holder thereof shall give notice to the Company of such holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such holder distributes Restricted Securities to an Affiliate of such holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.
2.13    Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earlier of (i) such time as such Holder owns less than fifty percent (50%) of the Registrable Securities held by such Holder immediately following the IPO and Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; or (ii) the tenth (10th) anniversary of the IPO.
15

3.    Information Rights.
3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor:
(a)    as soon as practicable, but in any event within one hundred eighty (180) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company;
(b)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);
(c)    as soon as practicable, but in any event within thirty (30) days after the end of each month, unaudited statements of income and cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); and
(d)    as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company.
If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.
Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.
3.2    Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; 
16

provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
3.3    Observer Rights; Additional Information.
(a)    As long as Catalyst Investors QP IV, L.P. (“Catalyst”) and its Affiliates own any shares of the Series B-1 Preferred Stock or Series C Preferred Stock, the Company shall invite a representative of Catalyst to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel. The Company shall reimburse the Catalyst observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Catalyst shall also have the right to receive from the Company (as soon as practicable following any request by Catalyst) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as Catalyst may from time to time reasonably request.
(b)    As long as LEC Weave Holdings LLC, a Delaware limited liability company (“Lead Edge”) and its Affiliates own any shares of the Series C Preferred Stock, the Company shall invite a representative of Lead Edge to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel. The Company shall reimburse the Lead Edge observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Lead Edge shall also have the right to receive from the Company (as soon as practicable following any request by Lead Edge) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as Lead Edge may from time to time reasonably request.
(c)    As long as Tiger Global Private Investment Partners XI, L.P. (“Tiger”) and its Affiliates own any shares of the Series D Preferred Stock, the Company shall 
17

invite a representative of Tiger to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel. The Company shall reimburse the Tiger observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Tiger shall also have the right to receive from the Company (as soon as practicable following any request by Tiger) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as Tiger may from time to time reasonably request.
3.4    Termination of Information Rights. The covenants set forth in Subsection 3.1 through Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Certificate, whichever event occurs first.
3.5    Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without, to such Investor’s knowledge, a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any shares of Preferred Stock from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor, to the extent legally permissible, promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.
4.    Rights to Future Stock Issuances.
4.1    Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major 
18

Investor shall be entitled to apportion the right of first offer hereby granted to it, in such proportions as it deems appropriate, among itself and its Affiliates. For purposes of this Subsection 4.1 (other than the immediately prior sentence), each of A-WQY-19-Fund, a series of AngelList-ER-Funds, LLC (“AngelList”), and Ed Roman shall be considered a Major Investor.
(a)    The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.
(b)    By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, all or any portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors (provided, that if the Fully Exercising Investors, collectively, elect to subscribe for more than the total number of unsubscribed shares which are available for purchase by them, then such unsubscribed shares shall be allocated among such Fully Exercising Investors based upon the relative number of shares of Common Stock held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investors, provided that no Fully Exercising Investor shall be obligated to purchase a total number of unsubscribed shares in excess of the number of shares it elected to purchase). The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).
(c)    If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived 
19

and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1.
(d)    The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Certificate); (ii) the issuance of shares of Series D Preferred Stock sold pursuant to the Purchase Agreement; and (iii) shares of Common Stock issued in the IPO.
4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO or (ii) upon a Deemed Liquidation Event, whichever event occurs first.
5.    Additional Covenants.
5.1    Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors.
5.2    Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.
5.3    Matters Requiring Board Approval. The Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors:
(a)    enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by this Agreement, the Purchase Agreement, and the agreements entered into in connection therewith, or transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors;
(b)    make any grant or award of options or stock, or amend any previous such grant or award of options or stock, to provide for acceleration of the vesting terms upon the occurrence of some future event;
20

(c)    incur or guarantee any indebtedness (other than trade credit incurred in the ordinary course of business);
(d)    approve any annual budget or long term plan representing a material variation from the business plan in effect as of the date hereof; or
(e)    enter into any transaction not in the ordinary course of business, including the acquisition of the securities or assets of another entity (other than purchases of goods in the ordinary course of business).
5.4    Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket expenses incurred (consistent with the Company’s travel policy and expense reimbursement policies) in connection with attending meetings of the Board of Directors. The Company shall cause to be established and will maintain an audit and compensation committee, each of which shall consist solely of non-management directors. The Series B-1 Director (as defined in the Certificate) and the Series B Director (as defined in the Certificate) shall be entitled in such person’s discretion to be a member of each committee of the Board of Directors.
5.5    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then, to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate, or elsewhere, as the case may be.
5.6    Termination of Covenants. The covenants set forth in this Section 5, except for Subsection 5.5, shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO or (ii) upon a Deemed Liquidation Event, whichever event occurs first.
6.    Miscellaneous.
6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a holder of Preferred Stock to a transferee that (i) is an Affiliate of such holder; (ii) is such holder’s Immediate Family Member or trust for the benefit of an individual holder or one or more of such holder’s Immediate Family Members; or (iii) after such transfer, holds at least 438,361 shares of Preferred Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the shares of Preferred Stock with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11; and provided further that the rights granted to AngelList, Ed Roman and Future Shape LLC under Subsection 4 may not be 
21

transferred or assigned and any purported transfer or assignment of such rights in violation of this Subsection 6.1 shall be null and void and shall have no force and effect. For the purposes of determining the number of shares of Preferred Stock held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a holder of Preferred Stock; (2) who is such holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual holder or such holder’s Immediate Family Member shall be aggregated together and with those of the transferring holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.
6.2    Governing Law. This Agreement shall be governed by the internal law of the State of Delaware.
6.3    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.
6.5    Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, it shall be sent to Weave Communications, Inc., 2000 W. Ashton Blvd, Ste #100, Lehi, UT 84043, Attention: Chief Executive Officer; and a copy (which shall not constitute notice) shall also be sent to Holland & Hart LLP, 222 South Main Street, Suite 2200, Salt Lake City, Utah 84101, Attention: Marc Porter; and if notice is given to the Investors, a copy shall also be given to Goodwin Procter LLP, The New York Times Building, 620 Eighth Avenue, New York, NY 10018, Attention: Paul N. 
22

Cicero, a copy shall also be given to Lowenstein Sandler LLP, 1251 Avenue of the Americas, 18th Floor, New York, NY 10020, Attention: Michael Brosse (mbrosse@lowenstein.com) and a copy shall also be given to Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, 220 West 42nd Street, 17th Floor, New York, NY 10036, Attention: Steven L. Baglio.
6.6    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party; and provided further that (a) any amendment to Subsection 3.1 or Subsection 3.2 shall also require the written approval of the holders of at least sixty percent (60%) of the outstanding shares of Series C Preferred Stock and the holders of a majority of the outstanding shares of Series D Preferred Stock and (b) any amendment to Subsection 3.3(a) shall also require the written approval of Catalyst, any amendment to Subsection 3.3(b) shall also require the written approval of Lead Edge and any amendment to Subsection 3.3(c) shall also require the written approval of Tiger. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
6.7    Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
6.8    Aggregation of Stock. All shares of Registrable Securities or Preferred Stock, as the case may be, held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.
23

6.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Series D Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series D Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.
6.10    Entire Agreement. Upon the effectiveness of this Agreement, the Existing Agreement shall be amended and restated to read in its entirety as set forth in this Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled, including without limitation the Existing Agreement.
6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (d) irrevocably consents to the service of the summons and complaint and any other process in any action or proceeding relating to the transactions contemplated by this Agreement in accordance with Subsection 6.5 or in such other manner as may be permitted by applicable law, and nothing in this Subsection 6.11 shall affect the right of any party to serve legal process in any other manner permitted by applicable law.
WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND 
24

VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.
The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction.
6.12    Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
6.13    Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.
[Remainder of Page Intentionally Left Blank]
25

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
									
		COMPANY:
			
		WEAVE COMMUNICATIONS, INC.
			
			
		By:	/s/ Brandon Rodman
			Brandon Rodman, Chief Executive Officer

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:

					
		TIGER GLOBAL PRIVATE INVESTMENT PARTNERS XI, L.P.

					
		By:
	Tiger Global PIP Performance XI, L.P.,

					its General Partner

					
		By:
	Tiger Global PIP Management XI, Ltd.,

					its General Partner

					
					
		By:
	/s/ Steve Boyd

		Name:
	Steve Boyd

		Title:
	General Counsel

					
					
		JOHN CURTIUS

					
					
		/s/ John Curtis

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:

					
		CATALYST INVESTORS QP IV, L.P.

					
		By:
	Catalyst Investors Partners IV, L.P.,

					its general partner

					
		By:
	Catalyst Investors Partners IV, L.L.C.,
					its general partner
					
					
		By:	/s/ Brian Rich
		Name:	Brian Rich
		Title:	President
					
		CATALYST INVESTORS IV, L.P.
					
		By:	Catalyst Investors Partners IV, L.P.,
					its general partner
					
		By:	Catalyst Investors Partners IV, L.L.C.,
					its general partner
					
					
		By:	/s/ Brian Rich
		Name:	Brian Rich
		Title:	President

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
									
		INVESTORS:
			
		CROSSLINK CROSSOVER FUND VIII, L.P.
			
		By:	Crossover Fund VIII Management, L.L.C.,
		its General Partner
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory
			
		CROSSLINK VENTURES VII, L.P.
			
		By:	Crosslink Ventures VII Holdings, L.L.C.,
		its General Partner
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory
			
		CROSSLINK VENTURES VII-B, L.P.
			
		By:	Crosslink Ventures VII Holdings, L.L.C.,
		its General Partner
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory
			
		CROSSLINK BAYVIEW VII, L.L.C.
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory
			
		CROSSLINK CROSSOVER FUND VII, L.P.
			
		By:	Crossover Fund VII Management, L.L.C.,
		its General Partner
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory
			
		BETA BAYVIEW, L.L.C.
			
			
		By:	/s/ Mihaly Szigeti
			Mihaly Szigeti, Authorized Signatory

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
									
		INVESTORS:
			
		PELION VENTURES VI, L.P.
			
		By:	Pelion Venture Partners VI, L.L.C.
		Its:	General Partner
			
			
		By:	/s/ Blake Modersitzki
			Blake Modersitzki, Partner
			
		PELION VENTURES VI-A, L.P.
			
		By:	Pelion Venture Partners VI, L.L.C.
		Its:	General Partner
			
			
		By:	/s/ Blake Modersitzki
			Blake Modersitzki, Partner

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:
					
		A CAPITAL PARTNERS, L.P.
					
		for itself and as nominee for
					
		A Capital Parallel Fund A, L.P. and
		A Capital Parallel Fund B, L.P.
					
		By:	A Capital Equity Partners, L.L.C.
		Its:	General Partner
		
					
		By:	/s/ Ronny Conway
		Name:	Ronny Conway
		Title:	Partner

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:
					
		FUTURE SHAPE LLC
					
		By:	Fund the Future Trust
		Its:	Manager
					
					
		By:	/s/ Tony Fadell
		Name:	Tony Fadell
		Title:	Trustee
		
		FUTURE SHAPE 1.5, LLC
					
		By:	Fund the Future Trust
		Its:	Manager
					
					
		By:	/s/ Tony Fadell
		Name:	Tony Fadell
		Title:	General Partner
					
		FUTURE SHAPE 1.5, L.P.
					
		By:	Concert Management, Inc.
		Its:	General Partner
					
					
		By:	/s/ Tony Fadell
		Name:	Tony Fadell
		Title:	CEO/President

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
																					
		INVESTORS:
							
		A-WQY-19-PR-FUND, A SERIES OF ANGELLIST-ER-FUNDS, LLC
							
		By:	Assure Fund Management, LLC
		Manager of the Fund
							
				
		By:	/s/ Keith Mayer
		Name of Manager:	Assure Fund Management, LLC
		Title:	Manager of the Fund
				
		A-WQY-19-FUND, A SERIES OF 
ANGELLIST-ER-FUNDS, LLC
			
		By:	Assure Fund Management, LLC
		Manager of the Fund
							
				
		By:	/s/ Keith Mayer
		Name of Manager: 	Assure Fund Management, LLC
		Title:	Manager of the Fund
							
		A-WEA-11-FUND, A SERIES OF ANGELLIST-ER-FUNDS, LLC
							
		By:	Assure Fund Management, LLC,
		Manager of the Fund
			
							
		By:	/s/ Keith Mayer
		Name of Manager: 	Assure Fund Management, LLC
		Title:	Manager of the Fund
							
		WEA FUND I, A SERIES OF HACK VC, LP
							
		By:	Fund GP, LLC, its General Partner
		By:	Belltower Fund Group, Ltd.
							
							
		By:	/s/ Isaiah Deporto-Plick
		Signatory:	Isaiah Deporto-Plick
							
		Title:	Authorized Person of the General Partner’s 
		Manager

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:
					
		LEC WEAVE HOLDINGS LLC
					
					
		By:	/s/ Nimay Mehta
		Name:	Nimay Mehta
		Title:	Authorized Person

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
															
		INVESTORS:
					
		BESSEMER VENTURE PARTNERS IX, L.P.
					
		By:	Deer IX & Co. L.P., its General Partner
		By:	Deer IX & Co. Ltd., its General Partner
					
					
		By:	/s/ Scott Ring
		Name:	Scott Ring
		Title:	General Counsel
		
		BESSEMER VENTURE PARTNERS IX INSTITUTIONAL, L.P.
					
		By:	Deer IX & Co. L.P., its General Partner
		By:	Deer IX & Co. Ltd., its General Partner
					
					
		By:	/s/ Scott Ring
		Name:	Scott Ring
		Title:	General Counsel

[Signature Page to Amended and Restated Investors’ Rights Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
									
		INVESTORS:
			
		ED ROMAN
			
			
		Signature:	/s/ Ed Roman

[Signature Page to Amended and Restated Investors’ Rights Agreement]

SCHEDULE A
Investors
Name and Address
Tiger Global Private Investment Partners XI, L.P.
c/o Tiger Global Management, LLC
[Address]
John Curtius
c/o Tiger Global Management, LLC
[Address]
LEC Weave Holdings LLC
[Address]
Catalyst Investors QP IV, L.P.
[Address]
Crosslink Crossover Fund VIII, L.P.
c/o Crosslink Capital
[Address]
Crosslink Ventures VII, L.P.
c/o Crosslink Capital
[Address]
Crosslink Ventures VII-B, L.P.
c/o Crosslink Capital
[Address]
Crosslink Bayview VII, LLC
c/o Crosslink Capital
[Address]
Crosslink Crossover Fund VII, L.P.
c/o Crosslink Capital
[Address]
Pelion Ventures VI-A, L.P.
[Address]
Y Combinator Continuity Fund I, L.P.
[Address]
Beta Bayview, LLC 
c/o Crosslink Capital
[Address]

Homebrew Ventures I, L.P.
[Address]
Fuel Capital I, L.P.
[Address]
Accelerate FC Fund IV LLC
[Address]
Liquid 2 LLC
[Address]
UA2, LLC
[Address]
Initialized Capital II, L.P.
[Address]
Hydrazine Capital, L.P.
[Address]
The Ralston Family Trust
[Address]
YCVC W14, LLC
[Address]
Paul Buchheit
[Address]
Bessemer Venture Partners IX, L.P.
[Address]
Bessemer Venture Partners IX Institutional, L.P.
[Address]
A-WQY-19-PR-FUND, a Series of Angellist-Er-Funds, LLC
[Address]
A-WQY-19-FUND, a Series of Angellist-Er-Funds, LLC
[Address]
A-WEA-11-FUND, a Series of Angellist-Er-Funds, LLC
[Address]
WEA Fund I, a series of Hack VC, LP
[Address]

Future Shape 1.5,
LP Future Shape 1.5,
LLC Future Shape, LLC
[Address]
Ed Roman
[Address]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]